Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARGX 
argenx NV ADR (ARGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: ARGX (4-star) is a STRONG-BUY. BUY since 62 days. Simulated Profits (41.01%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
22 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $852.53
1 Year Target Price $852.53
| 14 | Strong Buy |
| 7 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 55.08% | Avg. Invested days 58 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 52.30B USD | Price to earnings Ratio 43.3 | 1Y Target Price 852.53 |
Price to earnings Ratio 43.3 | 1Y Target Price 852.53 | ||
Volume (30-day avg) 22 | Beta 0.04 | 52 Weeks Range 510.06 - 855.46 | Updated Date 10/21/2025 |
52 Weeks Range 510.06 - 855.46 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 19.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 41.03% | Operating Margin (TTM) 21.08% |
Management Effectiveness
Return on Assets (TTM) 4.83% | Return on Equity (TTM) 24.72% |
Valuation
Trailing PE 43.3 | Forward PE 32.05 | Enterprise Value 44138721779 | Price to Sales(TTM) 16.76 |
Enterprise Value 44138721779 | Price to Sales(TTM) 16.76 | ||
Enterprise Value to Revenue 14.46 | Enterprise Value to EBITDA 64.01 | Shares Outstanding 61568926 | Shares Floating 61146679 |
Shares Outstanding 61568926 | Shares Floating 61146679 | ||
Percent Insiders - | Percent Institutions 53.11 |
Upturn AI SWOT
argenx NV ADR
Company Overview
History and Background
argenx NV ADR, founded in 2008, is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It focuses on developing antibody-based medicines targeting autoimmune and inflammatory conditions.
Core Business Areas
- Immunology: argenx develops and commercializes differentiated antibody-based medicines for the treatment of severe autoimmune diseases. Their approach involves engineering antibodies to modulate the immune system.
- Antibody Engineering: argenx utilizes its proprietary antibody engineering platform, SIMPLE Antibodyu2122, to create novel therapeutic antibodies.
- Commercialization: argenx is focused on building a global commercial infrastructure to support the launch and growth of its products.
Leadership and Structure
argenx NV ADR is led by Tim Van Hauwermeiren (CEO). The organizational structure includes research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- VYVGART (efgartigimod): VYVGART is a neonatal Fc receptor (FcRn) blocker approved for the treatment of generalized myasthenia gravis (gMG). It reduces IgG autoantibodies. Competitors include therapies from Alexion (Soliris, Ultomiris) and potentially other emerging treatments for gMG. Revenue for VYVGART in 2023 was approximately $1.2 billion.
- VYVGART Hytrulo: A subcutaneous formulation of efgartigimod co-formulated with hyaluronidase (endorsed for Adult gMG patients). Competitors include therapies from Alexion (Soliris, Ultomiris) and potentially other emerging treatments for gMG.
Market Dynamics
Industry Overview
The autoimmune disease market is large and growing, driven by an increasing prevalence of these conditions and the development of new therapies. There's significant unmet need for more effective and targeted treatments.
Positioning
argenx is positioned as an innovator in the autoimmune disease space, leveraging its antibody engineering platform to develop differentiated therapies. Its first approved product, VYVGART, has established a strong foothold in the gMG market.
Total Addressable Market (TAM)
The total addressable market for autoimmune disease therapies is estimated to be in the tens of billions of dollars annually. Argenx is well-positioned to capture a significant share of this market with VYVGART and its pipeline of other potential therapies.
Upturn SWOT Analysis
Strengths
- Novel antibody engineering platform (SIMPLE Antibodyu2122)
- Approved product (VYVGART) with demonstrated efficacy
- Strong pipeline of potential therapies
- Experienced management team
- Robust intellectual property portfolio
Weaknesses
- Reliance on a single approved product for revenue
- Commercialization is still in its early stages
- Pipeline development is subject to clinical trial risks
- Competition from established players in the autoimmune disease market
Opportunities
- Expansion of VYVGART into other indications
- Advancement of pipeline therapies through clinical development
- Strategic collaborations and acquisitions
- Growth in the autoimmune disease market
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from new and existing therapies
- Patent challenges
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- ALXN
- JAZZ
- UCB
Competitive Landscape
argenx has a competitive advantage in its FcRn blocking technology. However, established players like Alexion and UCB have significant resources and market presence.
Major Acquisitions
ILUZZION
- Year: 2021
- Acquisition Price (USD millions): 42.4
- Strategic Rationale: Strengthened its pipeline with a novel antibody targeting the IL-36 receptor.
Growth Trajectory and Initiatives
Historical Growth: argenx has experienced significant growth in recent years due to the launch and uptake of VYVGART.
Future Projections: Analysts project continued revenue growth for argenx driven by VYVGART and potential approvals of pipeline therapies.
Recent Initiatives: Recent initiatives include expanding VYVGART into new indications, advancing pipeline programs, and strengthening the commercial infrastructure.
Summary
Argenx is a promising biotechnology company focusing on autoimmune diseases. VYVGART's success drives growth, but reliance on a single product is a risk. Strong R&D and strategic acquisitions are positive. Argenx needs to navigate competition and clinical trial risks to realize its full potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- argenx NV ADR Investor Relations
- SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is based on available information and may not be precise. Financial data is approximate, based on available news, and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About argenx NV ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-05-18 | Co-Founder, CEO & Executive Director Mr. Timothy Van Hauwermeiren EMBA, M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1599 | Website https://argenx.com |
Full time employees 1599 | Website https://argenx.com | ||
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.